NRG-HN002
|
NRG
|
A Randomized Phase II Trial for Patients with p16 Positive; Non-Smoking Associated; Locoregionally Advanced Oropharyngeal Cancer
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
NRG-HN003
|
NRG
|
A Phase I and Expansion Cohort Study of Adjuvant Cisplatin; Intensity-Modulated Radiotherapy; and MK-3475 (Pembrolizumab) in High-Risk Head and Neck Squamous Cell Carcinoma (HNSCC)
|
Adult CIRB - Early Phase Emphasis
|
Completed
|
|
NRG-HN004
|
NRG
|
Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Locoregionally Advanced Head and Neck Cancer with a Contraindication to Cisplatin
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
NRG-HN005
|
NRG
|
A Randomized Phase II/III Trial of De-intensified Radiation Therapy for Patients with Early-Stage, p16-Positive, Non-Smoking Associated Oropharyngeal Cancer
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
NRG-HN006
|
NRG
|
Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy versus Elective Neck Dissection for Early-Stage Oral Cavity Cancer
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
NRG-HN007
|
NRG
|
An Open-Label, Phase III Study of Platinum-Gemcitabine with or without Nivolumab in the First-Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
|
Adult CIRB - Late Phase Emphasis
|
Completed
|
|
NRG-HN008
|
NRG
|
Phase I Trial with Expansion Cohort of DNA-PK Inhibition and IMRT in Cisplatin-Ineligible Patients with Stage 3-4 Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
|
Adult CIRB - Early Phase Emphasis
|
Available to Open
|
|
NRG-HN009
|
NRG
|
Randomized Phase II/III Trial of Radiation with High-Dose Cisplatin (100 mg/m2) Every Three Weeks Versus Radiation with Low-Dose Weekly Cisplatin (40 mg/m2) for Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
NRG-HN010
|
NRG
|
A Controlled, Randomized Phase II Trial of Docetaxel Plus Trastuzumab Versus Ado-Trastuzumab Emtansine for Recurrent, Metastatic, or Treatment-Naïve, Unresectable HER2-Positive Salivary Gland Cancer
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
NRG-HN011
|
NRG
|
A Randomized Phase II Study of Nivolumab Versus Nivolumab and BMS-986016 (Relatlimab) as Maintenance Treatment After First-Line Treatment with Platinum-Gemcitabine-Nivolumab for Patients with Epstein-Barr Virus-Associated Recurrent/Metastatic Nasopharyngeal Carcinoma (REMAIN)
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|